Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 11 2021
10 11 2021
Historique:
pubmed:
26
8
2021
medline:
21
12
2021
entrez:
25
8
2021
Statut:
ppublish
Résumé
The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL ( Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
Identifiants
pubmed: 34432481
doi: 10.1200/JCO.21.00006
pmc: PMC8577685
doi:
Types de publication
Clinical Trial, Phase II
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Webcast
Langues
eng
Sous-ensembles de citation
IM
Pagination
3623-3632Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233193
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233331
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Gynecol Oncol. 2014 Dec;135(3):583-5
pubmed: 25128606
Clin Oncol (R Coll Radiol). 2007 Sep;19(7):542-50
pubmed: 17624745
Gynecol Oncol. 2017 Sep;146(3):580-587
pubmed: 28687171
Gynecol Oncol. 2020 Feb;156(2):467-474
pubmed: 31837831
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1191-200
pubmed: 27130794
J Clin Oncol. 2012 Nov 1;30(31):3786-91
pubmed: 22753905
J Clin Oncol. 2008 Feb 20;26(6):884-9
pubmed: 18281661
Lancet Oncol. 2010 Jul;11(7):646-52
pubmed: 20537946
Gynecol Oncol. 2015 Jun;137(3):365-72
pubmed: 25868965